Per Norlén (CEO)

Per Norlén - born 1970, CEO since 2015, Chief Medical Officer (CMO) since 2010 – is a registered medical doctor with a doctoral degree and specialist doctor in clinical pharmacology, and associate professor in experimental and clinical pharmacology at Lund University. Per Norlén has 25 years of research experience in pharmacology including 14 years of experience in clinical drug development with a focus on clinical phase I/II studies. Member of the Management Team since 2010.

Other current positions: Board member of Atlas Therapeutics AB and A Bioscience Incentive AB.

Holdings in Alligator: 100,500 shares, 200,000 warrants and 250,000 employee stock options.

Per-Olof Schrewelius (CFO)

Per-Olof Schrewelius – Born 1963, Chief Financial Officer since 2016 – has an MSc in Business Administration and Economics from Lund University and has over 20 years of experience from different CFO and Finance Manager positions in various industries including medical technology and engineering. Member of the Management Team since 2016.

Other current positions: None

Holdings in Alligator: 10,000 shares and 125,000 warrants.

Christina Furebring (SVP Research and Development)

Christina Furebring – born 1964, Senior Vice President Research and Development since 2001 – is a Swedish graduate engineer and has a doctorate in immune technology from Lund University. She is also a co-founder of the FIND technology which is a cornerstone of Alligator’s technology platform. Christina Furebring has more than 20 years’ experience of working on the optimization of proteins and antibodies. Member of the Management Team since 2001.

Other current positions: Deputy Board Member in A Bioscience Incentive AB and Atlas Therapeutics AB.

Holdings in Alligator: 100,000 shares, 120,000 warrants and 150,000 employee stock options.

Rein Piir (VP Investor Relations)

Rein Piir – born 1958, Vice President Investor Relations since 2016 – is a Swedish graduate in business administration from Uppsala University and has many years of experience of providing consultancy services to stock market companies, including as a strategist at Alecta and head of analysis at Carnegie Investment Bank AB. Other experience includes CFO/Head of Investor Relations at Medivir AB and accountant at PricewaterhouseCoopers AB. Rein Piir currently also holds the position of VP Investor Relations at Camurus AB and Oncopeptides AB. Member of the Management Team since 2016.

Other current positions: Chairman and CEO of Piir & Partner AB.Board member of Integrative Research Laboratories Sweden AB, L. E. Svensson Snickeri Aktiebolag and Trygga Pengar i Mobilen Sverige AB.

Holdings in Alligator: 5,000 shares.